Journal of Clinical Pharmacology Publishes First Clinical Experience with Trevena's Heart Failure Biased Ligand TRV027 Jul 8, 2013 7:00 am EDT
Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure May 9, 2013 6:00 am EDT
Trevena to Present First-in-Man Study Results for Mu-Opioid Biased Ligand TRV130 Mar 18, 2013 9:00 am EDT
Trevena to present results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure Mar 8, 2013 9:00 am EST
Trevena GPCR platform yields a novel mu-opioid biased ligand analgesic with side effect benefits Jan 23, 2013 9:00 am EST
Trevena Completes First-in-Human Study of TRV130, an Injectable Mu-Opioid Biased Ligand for Acute Pain Nov 14, 2012 9:00 am EST
Trevena Presents Phase 1 Clinical Data for TRV027, a β-arrestin Biased AT1R Ligand, at the 2012 Heart Failure Society of America Meeting Sep 7, 2012 9:00 am EDT